All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Elena Zamagni, University of Bologna, Bologna, IT. We asked, How can MRD assessment help when treating patients with high-risk MM after transplantation?
How can MRD assessment help when treating patients with high-risk MM after transplantation?
In this video, Zamagni discusses how high-risk patients are treated the same as low/medium-risk patients, and can achieve a good response. Zamagni then talks about recent trials, including the MASTER trial, which highlights the difficulties faced by high-risk patients in maintaining MRD negativity. Finally, Zamagni discusses how consolidation therapy and better MRD monitoring could benefit high-risk patients.
ASH 2021 abstracts: What’s hot in multiple myeloma?
To help navigate the exciting content being presented at the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the...
ASH 2020| Practice-changing and breakthrough abstracts in multiple myeloma
The Multiple Myeloma Hub attended the virtual 62nd ASH Annual Meeting & Exposition, December, 5–8 2020, and has developed two downloadable resources, which provides...
Subscribe to get the best content related to multiple myeloma delivered to your inbox